Tiara

General characteristics. Structure:

Active ingredient: 2 mg of loperamide of a hydrochloride in 1 tablet.

Excipients: methyl silicone, potato starch, lactose (sugar milk), sucrose (sugar) cellulose microcrystallic, silicon dioxide colloid (aerosil), aspartame, povidone (Kollidon 90), ксилитол (Xylitab 300), лактитол, коллидон SR, menthol, magnesium stearate, anise oil.

Bystry and effective removal of symptoms of diarrhea.

Pharmacological properties:

Pharmacodynamics. Loperamide, contacting opioid receptors of an intestinal wall (modulation sincaline - and adrenergic neurons through guaninnukleotida), reduces a tone and motility of smooth muscles of intestines (at the expense of inhibition of release of acetylcholine and prostaglandins). Slows down a peristaltics and increases time of passing of intestinal contents.

Raises a tone of a proctal sphincter, promotes deduction of fecal masses and an urezheniye of desires to defecation. Action comes quickly and 4-6 hours proceed.

Pharmacokinetics. It is almost completely metabolized by a liver by conjugation. An elimination half-life (T1/2) – 9-14 h. It is removed preferential with bile and kidneys (in the form of the conjugated metabolites).

Indications to use:

Symptomatic treatment of acute and chronic diarrhea of various genesis (allergic, emotional, medicinal, beam; at change of a diet and qualitative structure of food, at disturbance of metabolism and absorption; as supportive application at diarrhea of infectious genesis.

Regulation of a chair at patients from ileostomy.

Route of administration and doses:

Inside, chewing, washing down with water. The adult at acute and chronic diarrhea appoint 2 tablets (4 mg) in an initial dose; then on 1 tablet (2 mg) after each act of defecation (in case of a liquid chair); the maximum daily dose – 8 tablets (16 mg). To children 6 years at acute diarrhea are more senior appoint in an initial dose 1 tablet (2 mg), then - on 1 tablet after each act of defecation (in case of a liquid chair); the maximum daily dose - 3 tablets (6 mg).

At normalization of a chair or in the absence of a chair more than 12 hours treatment by Diarra should be stopped.

Features of use:

At lack of effect within 48 hours use of drug it is necessary to stop and see a doctor.

Side effects:

Gastralgia, dryness in a mouth, allergic reactions (skin rash), drowsiness, dizziness, intestinal colic, nausea, vomiting, locks. Extremely seldom – intestinal impassability.

Contraindications:

Hypersensitivity to drug, a divertuculosis, intestinal impassability, ulcer colitis in an aggravation stage, diarrhea against the background of an acute pseudomembranous coloenteritis, in the form of monotherapy at dysentery and other infections of the digestive tract (DT); pregnancy (the I trimester), the lactation period, children up to 6 years.

With care: liver failure.

Overdose:

Symptoms: oppression of the central nervous system (CNS) - a stupor, a lack of coordination of movements, drowsiness, a miosis, a muscular hypertension, respiratory depression; intestinal impassability.

Treatment: an antidote – Naloxonum; considering that duration of effect of loperamide is more, than at Naloxonum, perhaps repeated introduction of the last.

Symptomatic treatment: absorbent carbon, gastric lavage, artificial ventilation of the lungs (AVL). Medical observation, at least, within 48 hours is necessary.

Storage conditions:

In the dry place protected from light at a temperature not above 25 °C. To store in the place, unavailable to children. A period of validity - 2 years. Not to apply after the period of validity specified on packaging.

Issue conditions:

Without recipe

Packaging:

Chewable tablets. On 4, 6, 7 or 10 tablets in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished. On 1, 2 or 3 blister strip packagings with the application instruction place in a pack from a cardboard.